Arch Neurol Chicago
-
Arch Neurol Chicago · Jun 2004
Comparative StudyDopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.
Dementia with Lewy bodies (DLB) is a common form of late-life dementia that can be difficult to differentiate from other disorders, especially Alzheimer disease (AD), during life. At autopsy the striatal dopaminergic transporter is reduced. ⋯ Dopamine transporter loss can be detected in vivo using FP-CIT SPECT in DLB. Further studies, especially of subjects with DLB without PD, are required to fully establish use in clinical practice.
-
Arch Neurol Chicago · Jun 2004
Comparative Study Clinical TrialEffectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy.
The treatment of painful diabetic polyneuropathy (DPN) is often inadequate and frequently limited by the systemic adverse effects of medications, necessitating the evaluation of novel treatments. ⋯ Up to four 5% lidocaine patches for up to 18 h/d are well tolerated in patients with painful diabetic polyneuropathy, significantly improve pain and quality-of-life ratings, and may allow tapering of concomitant analgesic therapy. Given the open-label design of this trial, a randomized controlled trial is necessary to confirm these results.
-
Arch Neurol Chicago · Jun 2004
Comparative StudyNo mutations in CACNA1A and ATP1A2 in probands with common types of migraine.
Mutations in CACNA1A, encoding a neuronal calcium channel subunit, and ATP1A2, encoding a catalytic subunit of a sodium-potassium-ATPase, have been found in some families with dominantly inherited hemiplegic migraine. ⋯ These 2 genes are not associated with more common migraine syndromes and are not the most common hemiplegic migraine genes.
-
Arch Neurol Chicago · Jun 2004
Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity.
Stiff-person syndrome (SPS) is an immune-mediated central nervous system disorder characterized by fluctuating muscle stiffness, disabling spasms, and heightened sensitivity to external stimuli. Up to 80% of patients with SPS have anti-glutamic acid decarboxylase (GAD) antibodies in the serum or cerebral spinal fluid (CSF). Whether these antibodies are clinically relevant and correlate with disease severity is unknown. ⋯ In patients with SPS, the anti-GAD antibody titers in serum and CSF do not correlate with disease severity or duration. Anti-GAD antibodies are an excellent marker for SPS, but monitoring their titers during the course of the disease may not be of practical value.
-
In humans, Menkes disease is the well-recognized neurological disorder due to inherited copper deficiency. Myelopathy due to acquired copper deficiency is not a well-recognized entity in humans, although myelopathy due to copper deficiency is well documented in some animal species. ⋯ Patients presenting with otherwise unexplained myelopathies should have their serum ceruloplasmin level measured.